Article

Mucosal Immunity and HIV-1 Infection: Applications for Mucosal AIDS Vaccine Development

Midwest Research Institute, 110 Thomas Johnson Drive, Suite 170 Frederick, MD 21702, USA.
Current topics in microbiology and immunology (Impact Factor: 3.47). 01/2011; 354:157-79. DOI: 10.1007/82_2010_119
Source: PubMed

ABSTRACT Natural transmission of human immunodeficiency virus type 1 (HIV-1) occurs through gastrointestinal and vaginal mucosa. These mucosal tissues are major reservoirs for initial HIV replication and amplification, and the sites of rapid CD4(+) T cell depletion. In both HIV-infected humans and SIV-infected macaques, massive loss of CD4(+) CCR5(+) memory T cells occurs in the gut and vaginal mucosa within the first 10-14 days of infection. Induction of local HIV-specific immune responses by vaccines may facilitate effective control of HIV or SIV replication at these sites. Vaccines that induce mucosal responses, in particular CD8(+) cytotoxic T lymphocytes (CTL), have controlled viral replication at mucosal sites and curtailed systemic dissemination. Thus, there is strong justification for development of next generation vaccines that induce mucosal immune effectors against HIV-1 including CD8(+) CTL, CD4(+) T helper cells and secretory IgA. In addition, further understanding of local innate mechanisms that impact early viral replication will greatly inform future vaccine development. In this review, we examine the current knowledge concerning mucosal AIDS vaccine development. Moreover, we propose immunization strategies that may be able to elicit an effective immune response that can protect against AIDS as well as other mucosal infections.

0 Followers
 · 
297 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mucosally produced thymic stromal lymphopoietin (TSLP) regulates Th2 responses by signaling to dendritic cells and CD4 T cells. Activated CD8 T cells express the TSLP receptor (TSLPR), yet a direct role for TSLP in CD8 T cell immunity in the mucosa has not been described. Because TSLP shares signaling components with IL-7, a cytokine important for the development and survival of memory CD8 T cells in systemic infection models, we hypothesized that TSLP spatially and nonredundantly supports the development of these cells in the respiratory tract. In this study, we demonstrate that influenza infection induces the early expression of TSLP by lung epithelial cells with multiple consequences. The global loss of TSLP responsiveness in TSLPR(-/-) mice enhanced morbidity and delayed viral clearance. Using a competitive adoptive transfer system, we demonstrate that selective loss of TSLPR signaling on antiviral CD8 T cells decreases their accumulation specifically in the respiratory tract as early as day 8 after infection, primarily due to a proliferation deficiency. Importantly, the subsequent persistence of memory cells derived from this pool was also qualitatively and quantitatively affected. In this regard, the local support of antiviral CD8 T cells by TSLP is well suited to the mucosa, where responses must be tempered to prevent excessive inflammation. Taken together, these data suggest that TSLP uniquely participates in local immunity in the respiratory tract and modulation of TSLP levels may promote long-term CD8 T cell immunity in the mucosa when other prosurvival signals are limiting.
    The Journal of Immunology 01/2014; 192(5). DOI:10.4049/jimmunol.1302085 · 5.36 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Animal and human data from various viral infections and vaccine studies suggest that nonneutralizing antibodies (nNAb) without neutralizing activity in vitro may play an important in protection against viral infection in vivo. This was illustrated by the recent RV144 HIV vaccine efficacy trial, which demonstrated that binding HIV-specific IgG-mediated nNAb directed against the V2 loop of HIV-1 envelope (Env) were correlated inversely with risk for HIV acquisition while Env-specific plasma IgA-mediated antibodies were directly correlated with risk. However, Tier 1 NAb in the subset of responders with low plasma Env-specific IgA correlated with decreased risk. Non-human primate SIV and SHIV challenge studies suggest that Env-mediated antibodies are essential and sufficient for protection. A comparison of immune responses generated in human efficacy trials reveals subtle differences in the fine specificity of the antibody responses, in particular in HIV-specific IgG subclasses. The underlying mechanisms that may have contributed to protection against HIV acquisition in humans, although not fully understood, are possibly mediated by antibody-dependent cell-mediated cytotoxicity (ADCC) and/or other non-neutralizing humoral effector functions such as antibody-mediated phagocytosis. The presence of such functional nNAb in mucosal tissues and cervico-vaginal and rectal secretions challenges the paradigm that NAb are the predominant immune response conferring protection, although this does not negate the desirability of evoking neutralizing antibodies through vaccination. Instead, NAb and nNAb should be looked as complementary or synergistic humoral effector functions. Several HIV vaccine clinical trials are on going to study these antibodies responses in various prime-boost modalities in the systemic and mucosal compartments. The induction of high frequency and titers of HIV-specific functional nNAb may represent an attractive hypothesis-testing strategy in future HIV vaccine efficacy trials.
    Clinical and vaccine Immunology: CVI 06/2014; 21(8). DOI:10.1128/CVI.00230-14 · 2.37 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The development of a safe and effective preventive HIV-1 vaccine remains a public health priority. Despite scientific difficulties and disappointing results, HIV-1 vaccine clinical development has, for the first time, established proof-of-concept efficacy against HIV-1 acquisition and identified vaccine-associated immune correlates of risk. The correlate of risk analysis showed that IgG antibodies against the gp120 V2 loop correlated with decreased risk of HIV infection, while Env-specific IgA directly correlated with increased risk. The development of vaccine strategies such as improved envelope proteins formulated with potent adjuvants and DNA and vectors expressing mosaics, or conserved sequences, capable of eliciting greater breadth and depth of potentially relevant immune responses including neutralizing and non-neutralizing antibodies, CD4+ and CD8+ cell-mediated immune responses, mucosal immune responses, and immunological memory, is now proceeding quickly. Additional human efficacy trials combined with other prevention modalities along with sustained funding and international collaboration remain key to bring an HIV-1 vaccine to licensure.
    Human Vaccines & Immunotherapeutics 03/2014; 10(6). DOI:10.4161/hv.28462 · 3.64 Impact Factor

Full-text

Download
152 Downloads
Available from
May 16, 2014